论文部分内容阅读
业已证实,干扰素IFN能降低慢性丙型肝炎患者的转氨酶,清除HCV RNA以及减轻肝脏炎症和坏死。研究旨在评估对干扰素治疗持久有效的慢性丙型肝炎患者的预后。 病人和方法:选择1988～1992年间肝穿刺证实的慢性丙型肝炎乃至肝硬化患者426例(16例失访),其中65％为慢性肝炎,35％存在肝硬化,所有患者血清HCV RNA均阳性。给予人淋巴母细胞α-n1 IFN 5MU/m~2或rIFNα-2b 10MU 1周3次肌注,2个月后,α-n1 IFN治疗者减量为3MU/m~2维持4或10个月;rIFNα-2b治疗者减量为5MU维持4个月后,将ALT复查者
Interferon IFN has been shown to reduce transaminases in patients with chronic hepatitis C, clear HCV RNA, and reduce liver inflammation and necrosis. The aim of the study was to evaluate the prognosis of patients with chronic hepatitis C who have long-lasting effects on interferon therapy. Patients and Methods: A total of 426 patients (16 lost) with chronic hepatitis C and cirrhosis confirmed by liver biopsy between 1988 and 1992 were selected. Among them, 65% were chronic hepatitis and 35% had cirrhosis. All patients had positive serum HCV RNA . Human lymphoblasts were given intramuscularly 3 times a week for α-n1 IFN 5MU / m 2 or rIFNα-2b 10MU. After 2 months, patients with α-n1 IFN treatment were reduced to 3 or 4 UU / m 2 Month; rIFNα-2b treatment was reduced to 5MU after 4 months, the ALT review